Compare · RBOT vs ZBH
RBOT vs ZBH
Side-by-side comparison of Vicarious Surgical Inc. (RBOT) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RBOT and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $15.96B, about 22.3x RBOT ($714.1M).
- Over the past year, RBOT is down 77.0% and ZBH is down 19.1% - ZBH leads by 58.0 points.
- ZBH has been more active in the news (6 items in the past 4 weeks vs 4 for RBOT).
- ZBH has more recent analyst coverage (25 ratings vs 6 for RBOT).
- Company
- Vicarious Surgical Inc.
- Zimmer Biomet Holdings Inc.
- Price
- $1.99-0.75%
- $82.40+2.90%
- Market cap
- $714.1M
- $15.96B
- 1M return
- +0.00%
- -8.87%
- 1Y return
- -77.03%
- -19.06%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- 2020
- News (4w)
- 4
- 6
- Recent ratings
- 6
- 25
Vicarious Surgical Inc.
Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest RBOT
- SEC Form 10-Q filed by Vicarious Surgical Inc.
- Vicarious Surgical Reports First Quarter 2026 Financial Results
- Vicarious Surgical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Amendment: SEC Form SCHEDULE 13D/A filed by Vicarious Surgical Inc.
- Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair
- Vicarious Surgical Begins Quotation on the OTCQB as Part of Strategic Path Toward Potential Nasdaq Listing
- SEC Form DEF 14A filed by Vicarious Surgical Inc.
- SEC Form 25-NSE filed by Vicarious Surgical Inc.
- SEC Form PRE 14A filed by Vicarious Surgical Inc.
- Vicarious Surgical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Latest ZBH
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zimmer Biomet Announces First Quarter 2026 Financial Results
- Zimmer Biomet Announces Chief Financial Officer Transition
- Zimmer Biomet Announces Webcast and Conference Call of First Quarter 2026 Financial Results
- Zimmer Biomet Appoints Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer
- SEC Form 4 filed by Noor Jehanzeb
- SEC Form 4 filed by Jafry Syed A.
- SEC Form 4 filed by Kolli Sreelakshmi
- SEC Form 4 filed by Shapiro Louis